Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.55 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 2/20 | 0.43 |
| ▸ | CCND1 | P24385 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | FABP4 | P15090 | 1/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31177216 | 0.87 | HTR2C (0.55) | HTR2CHTR2APPARGNPY5RLMNA | |
| SCHEMBL1576340 | 0.85 | KMT2A (0.60) | HTR2CHTR2APPARGNPY5RCDK4 | |
| SCHEMBL16234651 | 0.84 | HTR2C (0.55) | HTR2CHTR2APPARGNPY5RCDK4 | |
| SCHEMBL8248060 | 0.82 | NTSR1 (0.55) | PPARGLMNAF2KMT2AFAAH | |
| SCHEMBL2008953 | 0.81 | HTR2A (0.55) | HTR2CHTR2ALMNAKMT2AFAAH | |
| SCHEMBL2006946 | 0.81 | HTR2A (0.55) | HTR2CHTR2ANPY5RCDK4CCND1 | |
| SCHEMBL30261729 | 0.78 | HTR2C (0.68) | HTR2CHTR2APPARGNPY5RHDAC3 | |
| SCHEMBL20037274 | 0.78 | ALDH1A1 (0.50) | HTR2CHTR2APPARGNPY5R | |
| SCHEMBL18911985 | 0.77 | HTR2A (0.46) | HTR2CHTR2ANPY5RLMNAKMT2A | |
| SCHEMBL29955957 | 0.76 | KMT2A (0.71) | CDK4CCND1LMNAKMT2AHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620399-B1 | INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB PHARMA SA (BE) | 2010-09-22 | — | — | EP | claimed |
| US-20070043038-A1 | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB, S.A. (BE) | 2007-02-22 | — | — | US | claimed |
| CN-1768036-A | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB SA (BE) | 2006-05-03 | — | — | CN | claimed |
| US-7964593-B2 | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2011-06-21 | — | — | US | disclosed |
| EP-1799643-B1 | INDOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB PHARMA SA (BE) | 2010-09-22 | — | — | EP | disclosed |
| EP-1620399-B1 | INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB PHARMA SA (BE) | 2010-09-22 | — | — | EP | disclosed |
| US-20100069375-A1 | Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2010-03-18 | — | — | US | disclosed |
| US-7645887-B2 | 2-(5-iodo-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; epilepsy, epileptogenesis, seizure disorders and convulsion; 2-(5-chloro-2-oxo-2,3-dhydro-1H-indol-1-yl)-N-[6-(hydroxymethyl)cyclohex-3-en-1-yl]acetamide | UCB PHARMA, S.A. (BE) | 2010-01-12 | — | — | US | disclosed |
| US-7632856-B2 | Indolone derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2009-12-15 | — | — | US | disclosed |
| US-20090012147-A1 | Indolone Derivatives, Processes For Preparing Them And Their Uses | UCB PHARMA, S.A. (BE) | 2009-01-08 | — | — | US | disclosed |
| CN-100364973-C | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB SA (BE) | 2008-01-30 | — | — | CN | disclosed |
| EP-1799643-A1 | INDOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2007-06-27 | — | — | EP | disclosed |
| US-20070043038-A1 | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB, S.A. (BE) | 2007-02-22 | — | — | US | disclosed |
| CN-1768036-A | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB SA (BE) | 2006-05-03 | — | — | CN | disclosed |
| EP-1620399-A1 | INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2006-02-01 | — | — | EP | disclosed |
| WO-2006008067-A1 | INDOLONE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2006-01-26 | — | — | WO | disclosed |
| WO-2004087658-A1 | INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012147-A1 | Indolone Derivatives, Processes For Preparing Them And Their Uses | IDO1, IDO2, HTR3C | HTR2C 17/4885HTR2A 15/4885PPARG 1543/4885 |
| US-20100069375-A1 | Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses | AANAT, TPH2, CYP1A2 | HTR2C 445/4885HTR2A 159/4885PPARG 844/4885 |
| US-20070043038-A1 | Indolone-acetamide derivatives, processes for preparing them and their uses | AANAT, TPH2, CYP1A2 | HTR2C 445/4885HTR2A 159/4885PPARG 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.